Latest stories

Basket Bet

B

I wrote the following note to my subscribers on a recent position we have initiated. Specialty chemicals and Pharma is currently among the few sectors which have caught the fancy of the markets. I think these sectors do have the potential for above returns in the long term, though not every company will benefit equally from the tailwind.

The success or failure of each company will come down to the unique advantages/ competencies built by the management and their execution going forward. In addition to that, each company faces idiosyncratic (fancy word for unique) risks with FDA audits being one of them.

As a result, a single company bet can lead to losses even if rest of the sector does well

In order to mitigate this risk, I have taken a basket bet approach for the portfolio. This is also due to the fact, that one cannot estimate such risks ex-ante (before the fact). Diversification across the sector reduces, though does not eliminate the risk.

Pharma Sector bet

This is different from our usual transactions. This transaction is part of a sector bet. I am betting on the pharma sector for the following reasons

  • Several companies in the sector have been investing in R&D across a wide range of products such as Finished generics, API, Biosimilars and new dosage forms. As these investments have a long gestation period, the result is not fully visible in the P&L statement yet. We are now at the cusp of seeing the result of these investments, which have been made over the last 5+ years
  • Several companies have been investing on the front end (marketing) for the US and other markets. This allows the company to have a better control on the supply chain (with better margins) and work directly with customers. However, building the front end takes time and we are seeing early results of that.
  • The industry went through a growth phase till 2015, when it was hit by a mix of issues. The industry was hit by FDA audit failures which resulted in a loss of revenue for companies which failed the audit. At the same time, there was a consolidation of buyers (companies which buy pharmaceuticals for hospitals and pharmacies) which resulted in higher pricing pressure. This caused a drop in the growth and margins for the industry resulting in re-rating of the sector.
  • The industry has since then improved its processes and has a much better record of passing FDA audits. In addition to that, companies continue to invest in these processes to improve their compliance rate.
  • Several companies in the sector are now expanding beyond the US (and India) into other countries such as the EU, Japan and Africa. This should provide further growth opportunities for the sector.

We have an option to bet on a single company to play the above theme, but the risk of FDA audit and higher pricing pressures in some product segments continues to be high. I want to take advantage of this long-term tailwind and growth opportunity, but at the same time reduce the risk of failing an FDA audit.  Hence my plan is to go ahead with a sector bet where we will spread out our capital across a few attractive ideas.

I have not decided the number of companies or the size of the bet yet.

The ideas in this bucket – which I will call the pharma bet (PB) could be rotated in and out with a much higher frequency compared to other positions in our portfolio. I have been studying the sector for some time now and like a few other companies in this space. My plan is to add companies some of which could be long term plays whereas others could be more tactical in nature.

Throwing in the towel

T

-2%

-28%

-48%

This is what you have lost in the last three years if you invested in nifty 50 (large cap), Nifty Midcap 100 and Nifty Small cap 100. Even these numbers understate the actual losses. Large caps appear to be a safe haven, but even that is driven by a handful of companies.

One can find comments on media, comparing equities with other asset classes such as fixed deposit, gold etc. and implying that equities are doomed to perform poorly in the future.

I think such people are too lazy to look at the data. Equities over a 3, 5 and 10 year periods outperform all other asset classes. What is not stated that equities DO NOT outperform in ALL 3,5 and 10 year periods. This difference may appear to be subtle, but the effect of it is not.

The probability of equity underperforming other asset classes is as follows

3 Year rolling buckets     :             25%

5 Year rolling buckets     :             18%

10 Year rolling buckets   :             10%

What the above stats mean is that for every 3-year rolling period, equities can underperform other asset classes such as fixed income, one out of three times. The recent 3- and 5-year period has been one of those times. This is another representation of risk, namely that a particular asset class will underperform from time to time.

If you are losing patience with equities as an asset class, there are two questions you need to answer for yourself

Do I believe equities as an asset class will deliver high returns in the future?

The way to look at this question is to look at the last 100+ year of data across countries. This data supports the view that equities do outperform all other asset classes over the long run. However, there are periods of underperformance which test the patience of almost all investors.

Do I believe the fund manager can deliver above returns?

The way to look at this question is to look at the performance of this individual/fund house over the long run (across market cycles). Different styles are in favor at different points of time. 2014-2017 saw small and midcaps do well. Large caps, especially quality has done well in the last two years. In order to eliminate the chance of luck, look at the performance of the manager over a 5 to 10-year period and check if the investment approach makes sense to you (and suits your temperament).

There is no magic pill which will convince you to invest in equities. Data can help you make a rational decision, but at different points of time in your investment journey, you will need some blind faith to keep going.

I have been through such periods in the past (in different aspects of life including investing) and often faith supported by data has worked for me.

Regret minimization

R

I shared a framework in the previous post on how I am analyzing  my current positions to evaluate the risk. Some of the companies in the portfolio have applied for a debt moratorium which if accepted, reduces risk for the company. At the same time other companies plan to raise debt to fund working capital due to the drop-in revenue.

We are likely to see similar actions by other companies across the spectrum (debt moratorium, debt or equity raise)

I have been running a similar filter on the new ideas too, which need to have the capacity to sustain operations for a year without running out of cash (either from operations, balance sheet or through borrowings)

Regret minimization

This is a lot of discussion in the media and investor community on the shape of the recovery – will it be a V, U, W or some other form. In my mind, this is an important but unknowable factor. It depends on the following factors which cannot be forecasted with any certainty.

  • How long will the lock down last?
  • Will the lock down be lifted in phases (both in terms of time and geography)?
  • How will this event impact consumer behavior (short and long term)?

How does one invest under such extreme uncertainty? One option is to assume that there will be a quick recovery and go all in. The other extreme is to wait till it is all clear and then deploy the capital. In the first approach one is making a bet on a specific scenario which may not occur, leading to sub-par results. In the second case, we may end up with sub-par returns too but only because prices will adjust once all the uncertainty goes away.

Under the circumstances, my approach is that of ‘regret minimization’. That’s a fancy way of saying that I will do something in middle, so that I can avoid FOMO (fear of missing out) if the first scenario occurs, but at the same time have enough dry powder available incase the economic recovery takes longer.

I continue to look for companies which can survive the crisis and will add them to the portfolio in a staggered fashion. We will not be able to pick the absolute bottom or make the highest possible return, but at the same time will be able to avoid any extreme outcome.

Obsession with market bottom

There is a lot of chatter on social media and I have received some emails on this point too. The question usually is – Has the market bottomed or is it some way to go? The true question which people are asking is this – Is it safe now to buy stocks considering that the market has already passed its bottom?

Although there are some technical approaches which are used for finding market bottoms, I am in the camp that no one knows for sure and it is not even worth knowing. I personally think an obsession with market bottom is worse than a waste of time. It will impact your thinking and corrode your decision making.

If you agree with the analysis in my previous note, our focus should be on solvency and survivability of the companies we hold or plan to add. If a company can survive the next 1-2 years and its business model is not impacted, then it makes sense to start buying the stock if the valuation is attractive. This assumes that the company has good prospects in the long run.

We started adding to our positions recently and it is quite possible that the market and our portfolio could drop from the current levels. I am however not concerned with such losses. I am more focused on the short-term health and long-term prospects of the companies we hold.

Impact of one year

Let’s review the first principle of investing – The value of a company is the sum of discounted cash flow from now to the time when the company closes/goes out of business or is bought out.

If we analyze a company and conclude that it can survive the next 1-2 years of stress without an impact to the long-term business model, then it comes down to evaluating the impact of the epidemic to the fair value of the company.

Let’s assume that the company will not have any profits for 1-2 years. If you run a DCF with this assumption, the intrinsic value reduces by 8-12% depending on the assumptions around growth, return on capital etc. If that is the case, then most companies have corrected much more, and the market is assuming a worse outcome for them.

To be fair, a DCF is just one input and the market does not work on pure math and logic. The point I am trying to make here is that if we can buy or hold companies (based on our framework) which survive the next 1-2 years, without an impact to their long-term prospects, then the long-term returns would be good.

If you agree with the above approach, does it really matter if we are able to catch the bottom of the market or a particular stock? As I have said repeatedly in the past – If I get the analysis of a company wrong, a 10-20% difference in buy price will not make a difference. The key is to get the analysis right.

Changing my mind frequently

A lot of assumptions and expectations have changed in the last few months. What was considered impossible (locking down an entire country) has happened now. In such an environment, where facts keep changing, it is important to keep an open mind.

I am following the news as everyone else and do not have any special crystal ball to see the future. As a result, it is important to change your mind and not hold onto old assumptions. I did that in the early part of the year when I suddenly became bearish and raised the amount of cash in the portfolio.

We are adding to the portfolio (in a staggered fashion) but this is not based on some specific forecast. If the situation changes, I will change my stance again. Please be ready and prepared for any decisions I take.

Stress testing the portfolio

S

< Company names and details of the same have been removed>

To all subscribers,

I have been asked about the impact of the ongoing epidemic (Covid19) on our portfolio companies. I have been doing this analysis and this note is to describe the process. This is a probabilistic exercise which depends on the following factors

  • How long will the lock down last?
  • Will the lock down be lifted in phases (both in terms of time and geography)
  • How will this event impact consumer behavior (short and long term)?

All the above factors are important, but unknowable for now. We have a range of guesses floating around with unknown probabilities. Instead of trying to guess what is going to happen, I have tried to analyze this situation in a different fashion. I have broken down the problem into three-time buckets with a specific set of questions for each bucket

Short term bucket (3months)

  • Does the company face bankruptcy risk (due to zero revenue)
  • What is the liquidity situation for the company? In other words, does the company have enough cash/ access to credit to tide over this period

Medium term bucket (3-9 months)

  • What is the break even revenue for the company at which it can it can sustain its manpower expenses and mandatory overheads (rent, power etc)

Long term bucket (> 9 months)

  • Is the long term demand for the company impacted by this event?
  • Will the consumer behavior change permanently such that the company’s business model will be impacted?

The above questions are crude approximations and I am not trying to come up with a numerical impact on fair values. I have seen some analyst reports where they have changed the target price by X%. Putting a number, does not change the fact that this is still a guess.

Some of the conference calls by company managements show that they are also grappling with the unknown and do not have visibility on the numbers. To assume that an outside investor can do better is silly.

I have evaluated these questions using the following data points

  • Liquidity risk/ Credit report from ratings agencies
  • Company annual reports/ financial statements to evaluate how long the company can survive with zero revenue and the level of topline needed for break even
  • Management commentary

The stocks in the model portfolio are arranged based on their risk profile. This sequence is again a rough approximation of the risk. What this means is that company 2 is not more risky than Company 1, but Company 2 has lower risk than Company 14 which is at the bottom of the portfolio.

Dynamic situation

The impact on each company will depend on how long the lockdown lasts, whether it is consumer facing and the fragility of its balance sheet. In our case, most of our portfolio companies (other than financials) have low to zero debt. There is only one position which has high debt levels and is exposed to the consumer. As a result, this company is the lowest in the model portfolio and has been on hold much before the current situation (old subscribers including me continue to hold it).

I will be addressing a few more topics in my next post with the above framework in mind.

Subscription

Enter your email address if you would like to be notified when a new post is posted:

I agree to be emailed to confirm my subscription to this list

Recent Posts

Select category to filter posts

Archives